Inhibition of α-synuclein aggregation by small heat shock proteins

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 10, 2011, Pages 2956-2967

  Bruinsma, Ilona B ^a   Bruggink, Kim A ^a   Kinast, Karsten ^a   Versleijen, Alexandra A M ^a   Segers Nolten, Ine M J ^b   Subramaniam, Vinod ^b   Bea Kuiperij, H ^a   Boelens, Wilbert ^c   de Waal, Robert M W ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

synuclein; synucleinopathy; Aggregation; Fibrillization; Small heat shock proteins

Indexed keywords

ALPHA CRYSTALLIN; ALPHA SYNUCLEIN; HEAT SHOCK PROTEIN 20; HEAT SHOCK PROTEIN 22; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN B2B3; SMALL HEAT SHOCK PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; BINDING AFFINITY; BINDING KINETICS; GENE MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE;

ALPHA-SYNUCLEIN; HEAT-SHOCK PROTEINS; HEAT-SHOCK PROTEINS, SMALL; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MICROSCOPY, ATOMIC FORCE; MUTATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SURFACE PLASMON RESONANCE;

EID: 80052569506     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23152     Document Type: Article

References (54)

1. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18 Suppl 6: S2-S12.
2. Forster E, Lewy FH. Paralysis agitans. In: Lewandowsky M, editor. Pathologische Anatomie. Handbuch der Neurologie. Berlin: Springer Verlag; 1912.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
4. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000; 920: 16-27.
5. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-272.
6. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404: 394-398.
7. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000; 287: 1265-1269.
8. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999; 58: 120-129.
9. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35: 13709-13715.
10. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000; 97: 571-576.
11. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT, Jr. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322: 1089-1102.
12. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 2006; 351: 631-638.
13. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008; 3: e1867.
14. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, McLean PJ. CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 2008; 283: 17962-17968.
15. Xue WF, Hellewell AL, Gosal WS, Homans SW, Hewitt EW, Radford SE. Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem 2009; 284: 34272-34282.
16. Xue WF, Hellewell AL, Hewitt EW, Radford SE. Fibril fragmentation in amyloid assembly and cytotoxicity: When size matters. Prion 2010; 4: 20-25.
17. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
18. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di IG, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
19. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez TE, del ST, Munoz DG, de Yebenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-173.
20. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT, Jr. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 2007; 46: 7107-7118.
21. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001; 40: 11604-11613.
22. Ecroyd H, Carver JA. Crystallin proteins and amyloid fibrils. Cell Mol Life Sci 2009; 66: 62-81.
23. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. TorsinA and heat shock proteins act as molecular chaperones: Suppression of alpha-synuclein aggregation. J Neurochem 2002; 83: 846-854.
24. Sun Y, MacRae TH. Small heat shock proteins: Molecular structure and chaperone function. Cell Mol Life Sci 2005; 62: 2460-2476.
25. Kappe G, Franck E, Verschuure P, Boelens WC, Leunissen JA, de Jong WW. The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones 2003; 8: 53-61.
26. Iwaki T, Wisniewski T, Iwaki A, Corbin E, Tomokane N, Tateishi J, Goldman JE. Accumulation of alpha B-crystallin in central nervous system glia and neurons in pathologic conditions. Am J Pathol 1992; 140: 345-356.
27. Kappe G, Verschuure P, Philipsen RL, Staalduinen AA, Van de BP, Boelens WC, de Jong WW. Characterization of two novel human small heat shock proteins: Protein kinase-related HspB8 and testis-specific HspB9. Biochim Biophys Acta 2001; 1520: 1-6.
28. Lowe J, Errington DR, Lennox G, Pike I, Spendlove I, Landon M, Mayer RJ. Ballooned neurons in several neurodegenerative diseases and stroke contain alpha B crystallin. Neuropathol Appl Neurobiol 1992; 18: 341-350.
29. Lowe J, McDermott H, Pike I, Spendlove I, Landon M, Mayer RJ. Alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol 1992; 166: 61-68.
30. Sugiyama Y, Suzuki A, Kishikawa M, Akutsu R, Hirose T, Waye MM, Tsui SK, Yoshida S, Ohno S. Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation. J Biol Chem 2000; 275: 1095-1104.
31. Wilhelmus MM, Boelens WC, Otte-Holler I, Kamps B, Kusters B, Maat-Schieman ML, de Waal RM, Verbeek MM. Small heat shock protein HspB8: Its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol (Berl) 2006; 111: 139-149.
32. Wilhelmus MM, Otte-Holler I, Wesseling P, de Waal RM, Boelens WC, Verbeek MM. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol Appl Neurobiol 2006; 32: 119-130.
33. Rekas A, Adda CG, Andrew AJ, Barnham KJ, Sunde M, Galatis D, Williamson NA, Masters CL, Anders RF, Robinson CV, Cappai R, Carver JA. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: Effects on amyloid fibril formation and chaperone activity. J Mol Biol 2004; 340: 1167-1183.
34. Waudby CA, Knowles TP, Devlin GL, Skepper JN, Ecroyd H, Carver JA, Welland ME, Christodoulou J, Dobson CM, Meehan S. The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation. Biophys J 2010; 98: 843-851.
35. Wilhelmus MM, Boelens WC, Otte-Holler I, Kamps B, de Waal RM, Verbeek MM. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res 2006; 1089: 67-78.
36. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 2002; 322: 383-393.
37. van Raaij ME, Segers-Nolten IM, Subramaniam V. Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants. Biophys J 2006; 91: L96-L98.
38. Levine H, III. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 1993; 2: 404-410.
39. van der Werf KO, Putman CAJ, de Grooth BG, Segerink FB, Schipper EH, van Hulst NF, Greve J. Compact stand-alone atomic force microscope. Rev Sci Instrum 1993; 64: 2892-2897.
40. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999; 274: 19509-19512.
41. Zourlidou A, Payne S, Latchman DS. HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem 2004; 88: 1439-1448.
42. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: Kinases, phosphatases, functions and pathology. Cell Mol Life Sci 2009; 66: 3289-3307.
43. Ecroyd H, Meehan S, Horwitz J, Aquilina JA, Benesch JLP, Robinson CV, Macphee CE, Carver JA. Mimicking phosphorylation of αB-crystallin affects its chaperone activity. Biochem J 2007, 401: 129-141.
44. Lindner RA, Treweek TM, Carver JA. The molecular chaperone alpha-crystallin is in kinetic competition with aggregation to stabilize a monomeric molten-globule form of alpha-lactalbumin. Biochem J 2001; 354: 79-87.
45. Sathish HA, Koteiche HA, McHaourab HS. Binding of destabilized betaB2-crystallin mutants to alpha-crystallin: The role of a folding intermediate. J Biol Chem 2004; 279: 16425-16432.
46. Crippa V, Sau D, Rusmini P, Boncoraglio A, Onesto E, Bolzoni E, Galbiati M, Fontana E, Marino M, Carra S, Bendotti C, De BS, Poletti A. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum Mol Genet 2010; 19: 3440-3456.
47. Carra S, Sivilotti M, Chavez Zobel AT, Lambert H, Landry J. HspB8, a small heat shock protein mutated in human neuromuscular disorders, has in vivo chaperone activity in cultured cells. Hum Mol Genet 2005; 14: 1659-1669.
48. Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng 2002; 4: 155-174.
49. Tanaka M, Collins SR, Toyama BH, Weissman JS. The physical basis of how prion conformations determine strain phenotypes. Nature 2006; 442: 585-589.
50. Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM. An analytical solution to the kinetics of breakable filament assembly. Science 2009; 326: 1533-1537.
51. Rekas A, Jankova L, Thorn DC, Cappai R, Carver JA. Monitoring the prevention of amyloid fibril formation by alpha-crystallin. FEBS J 2007; 274: 6290-6304.
52. Aquilina JA, Benesch JL, Bateman OA, Slingsby C, Robinson CV. Polydispersity of a mammalian chaperone: Mass spectrometry reveals the population of oligomers in alphaB-crystallin. Proc Natl Acad Sci U S A 2003; 100: 10611-10616.
53. Bisaglia M, Mammi S, Bubacco L. Structural insights on physiological functions and pathological effects of α-synuclein. FASEB J 2008.
54. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283: 29639-29643.